Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 2.29 EUR 4.57% Market Closed
Market Cap: 106.7m EUR
Have any thoughts about
Heidelberg Pharma AG?
Write Note

Heidelberg Pharma AG
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Heidelberg Pharma AG
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Heidelberg Pharma AG
XETRA:HPHA
Current Portion of Long-Term Debt
€113.2k
CAGR 3-Years
4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Current Portion of Long-Term Debt
€28.1m
CAGR 3-Years
67%
CAGR 5-Years
29%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Current Portion of Long-Term Debt
€5.8m
CAGR 3-Years
13%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Current Portion of Long-Term Debt
€2.6m
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Current Portion of Long-Term Debt
€181.9m
CAGR 3-Years
174%
CAGR 5-Years
92%
CAGR 10-Years
38%
Formycon AG
XETRA:FYB
Current Portion of Long-Term Debt
€21.7m
CAGR 3-Years
180%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Heidelberg Pharma AG
Glance View

Market Cap
106.7m EUR
Industry
Biotechnology

Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 89 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.

HPHA Intrinsic Value
2.65 EUR
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Heidelberg Pharma AG's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
113.2k EUR

Based on the financial report for Nov 30, 2023, Heidelberg Pharma AG's Current Portion of Long-Term Debt amounts to 113.2k EUR.

What is Heidelberg Pharma AG's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
4%

Over the last year, the Current Portion of Long-Term Debt growth was 20%. The average annual Current Portion of Long-Term Debt growth rates for Heidelberg Pharma AG have been 4% over the past three years .

Back to Top